LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).

被引：0
作者：
McDermott, David F.
Peer, Avivit
Agarwal, Neeraj
Atkins, Michael B.
Cornell, Jerry
Perini, Rodolfo F.
Grossmann, Kenneth F.
Gurney, Howard
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Rambam Hlth Care Campus, Haifa, Israel
[3] Huntsman Canc Inst, Salt Lake City, UT USA
[4] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Merck & Co Inc, Rahway, NJ USA
[6] Westmead Hosp, Sydney, NSW, Australia
[7] Macquarie Univ, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4603
引用
收藏
页数：1
相关论文
共 50 条
[31]   PHASE I/II STUDY OF DEXNIGULDIPINE AND DOXORUBICINE IN ADVANCED RENAL-CELL CARCINOMA (RCC) [J].
GEHLING, U ;
WEIMAR, C ;
SCHULER, U ;
RATHGEB, F ;
EHNINGER, G ;
SCHUMACHER, K ;
HAVEMANN, K .
FASEB JOURNAL, 1995, 9 (03) :A96-A96
[32]   Current treatment in advanced renal cell carcinoma (RCC): Impact of targeted therapies in the management of RCC [J].
Bellmunt, Joaquim .
EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (07) :484-491
[33]   Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC). [J].
Choueiri, Toni K. ;
Bedke, Jens ;
Karam, Jose A. ;
Mckay, Rana R. ;
Motzer, Robert J. ;
Pal, Sumanta Monty ;
Suarez, Cristina ;
Uzzo, Robert ;
Liu, Hong ;
Burgents, Joseph E. ;
Sharma, Manish ;
Powles, Thomas .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[34]   Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. [J].
Eisen, T. ;
Bukowski, R. M. ;
Staehler, M. ;
Szczylik, C. ;
Oudard, S. ;
Stadler, W. M. ;
Schwartz, B. ;
Simantov, R. ;
Shan, M. ;
Escudier, B. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :223S-223S
[35]   Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study [J].
Luis Perez-Gracia, Jose ;
Castellano, Daniel ;
Angel Climent, Miguel ;
Mellado, Begona ;
Suarez, Cristina .
MEDICAL ONCOLOGY, 2019, 36 (03)
[36]   Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study [J].
José Luis Pérez-Gracia ;
Daniel Castellano ;
Miguel Ángel Climent ;
Begoña Mellado ;
Cristina Suárez .
Medical Oncology, 2019, 36
[37]   A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma [J].
Witte, RS ;
Leong, T ;
Ernstoff, MS ;
Krigel, RL ;
Oken, MM ;
Harris, J ;
Tormey, DC ;
Trump, DL .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) :241-247
[38]   Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC). [J].
Choueiri, Toni K. ;
Plimack, Elizabeth R. ;
Powles, Thomas ;
Voss, Martin H. ;
Gurney, Howard ;
Silverman, Rachel Kloss ;
Perini, Rodolfo F. ;
Rodriguez-Lopez, Karla ;
Rini, Brian I. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[39]   A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) [J].
Sternberg, C. N. ;
Szczylik, C. ;
Lee, E. ;
Salman, P. V. ;
Mardiak, J. ;
Davis, I. D. ;
Pandite, L. ;
Chen, M. ;
McCann, L. ;
Hawkins, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[40]   CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC) [J].
Motzer, Robert J. ;
Escudier, Bernard ;
Mcdermott, David F. ;
George, Saby ;
Hammers, Hans J. ;
Srinivas, Sandhya ;
Tykodi, Scott S. ;
Sosman, Jeffrey A. ;
Procopio, Giuseppe ;
Plimack, Elizabeth R. ;
Castellano, Daniel ;
Gurney, Howard ;
Donskov, Frede ;
Bono, Petri ;
Wagstaff, John ;
Gauler, Thomas C. ;
Ueda, Takeshi ;
Xu, Li-An ;
Waxman, Ian M. ;
Sharma, Padmanee .
BJU INTERNATIONAL, 2015, 116 :17-17
12345